We are aware of two vaccines in late clinical development (Phase 2 completed) globally to address a significant medical need for pregnant women and their offspring, one from Pfizer in the United States and one from...
In the wake of the COVID19 pandemic and the evolution of mRNA vaccines, the global vaccine industry in 2025 is characterized by rapid expansion of manufacturing capacity, especially for mRNA and other novel platforms...
Download Infographic Overview A live attenuated vaccine against varicella (later also used to prevent zoster) was developed in 1974 by Takahashi and colleagues. The varicella vaccine was licensed for universal...
Question: I received Zostavax 10 years ago. Can I now get vaccinated with Shingrix? Answer: Yes. The Evidence. The study referenced below shows that the Shingrix is immunogenic and well-tolerated in older adults who had...
The World Health Organization provides a detailed report on the Ebola virus disease (EVD) outbreak that occurred in the Bulape Health Zone of Kasai Province, Democratic Republic of the Congo (DRC), in 2025. The Ministry...
In a NEJM Perspective, 12 former FDA commissioners warn that new internal FDA directives on vaccine regulation threaten evidence‑based policy, innovation, and public health. The piece responds to a memo by the current...
Download Infographic Overview Infectious diseases (ID) are a major cause of morbidity and mortality in immunocompromised hosts (ICH). IDs may also trigger underlying conditions, graft-versus-host disease (GVHD), or...
Critical Summary This article evaluates the cost-effectiveness of recently available respiratory syncytial virus (RSV) immunization options—nirsevimab (a long-acting monoclonal antibody) and the maternal RSVpreF...
Critical Summary The article by Malkin et al. presents the results of a phase 1, double-blind, randomized clinical trial evaluating the safety and immunogenicity of the rVSVΔG-LASV-GPC vaccine, a recombinant vesicular...
This narrative review by Gromer et al. provides a comprehensive synthesis of the long-observed but poorly characterized relationship between vaccine reactogenicity—short-term, inflammatory adverse events—and...